<DOC>
	<DOCNO>NCT00719849</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy total-body irradiation donor umbilical cord blood transplant help stop growth cancer abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well donor umbilical cord blood transplant reduce intensity conditioning work treat patient advanced hematological cancer disease .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Transplant Treating Patients With Advanced Hematological Cancer Other Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate probability survival 1 year patient advance hematological malignancy disease treat non-myeloablative unrelated donor umbilical cord blood transplantation . Secondary - Six month non-relapse mortality . - Chimerism day 7 , 14 , 21 , 28 , 56 , 80 , 6 month , 1 2 year . - To determine incidence neutrophil engraftment day 42 . - To determine incidence platelet engraftment 6 month . - To determine incidence grade II-IV III-IV acute graft-versus-host-disease ( GVHD ) day 100 . - To determine incidence chronic GVHD 1 year . - To determine incidence clinically significant infection 6 month 1 2 year . - To determine probability progression-free survival 1 2 year . - To determine probability survival 2 year . - To determine incidence relapse disease progression 1 2 year . OUTLINE : Patients stratify accord disease status prior therapy ( hematologic malignancy disease treat autologous stem cell transplant ≥ 2 course multiagent chemotherapy within past 3 month vs hematologic malignancy disease treat autologous stem cell transplant &gt; 12 month ago ≤ 1 course multiagent chemotherapy immunosuppressive chemotherapy within past 3 month vs refractory leukemia lymphoma patient render aplastic either induction chemotherapy radioimmunoconjugated monoclonal antibody therapy ) . - Conditioning regimen : Patients receive fludarabine phosphate IV 1 hour day -6 -2 cyclophosphamide IV day -6 . Patients also undergo total body irradiation day -1 . Some patient also receive anti-thymocyte globulin IV day -6 -4 . - Umbilical cord blood transplantation ( UCBT ) : Patients undergo UCBT day 0 . - Immunosuppressive therapy ( graft-versus-host disease prophylaxis ) : Patients receive cyclosporine IV 1 hour orally ( tolerate ) every 8 12 hour begin day -3 continue approximately 6 month . Patients also receive mycophenolate mofetil IV every 8 hour day -3 5 orally day 6-30 . After completion study treatment , patient follow 6 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine Phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance hematologic malignancy disease curable conventional chemotherapy , include follow : Acute myeloid leukemia complete remission ( CR ) * ( define hematologic recovery , &lt; 5 % blast bone marrow morphology , cellularity &gt; 15 % ) , meet one follow criterion : In first complete remission ( CR1 ) AND highrisk disease evidence follow : Preceding myelodysplastic syndrome ( MDS ) Highrisk cytogenetics ( e.g. , monosomy 5 7 , define refer institution treatment protocol ) Required &gt; 2 course therapy obtain CR Erythroblastic megakaryocytic leukemia In second CR ( CR2 ) beyond Acute lymphoblastic leukemia CR* ( define hematologic recovery , &lt; 5 % blast bone marrow morphology , cellularity &gt; 15 % ) , meet one follow criterion : In CR1 AND highrisk disease evidence follow : ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL rearrangements Hyplodiploid Required &gt; 1 course therapy obtain CR Beyond CR2 Chronic myelogenous leukemia ( CML ) All type allow ( except refractory blast crisis CML ) Patients chronic phase CML must fail intolerant prior imatinib mesylate ( Gleevec ) tyrosine kinase inhibitor MDS Any subtype allow ( include refractory anemia [ RA ] ) Severe pancytopenia complex cytogenetics Blasts must &lt; 5 % ( blast ≥ 5 % , pretransplant induction therapy require reduce blast count &lt; 5 % ) Large cell lymphoma , Hodgkin lymphoma , multiple myeloma , meet one follow criterion : Chemotherapysensitive disease fail prior therapy Patients large cell lymphoma Hodgkin lymphoma must progressive disease salvage therapy ( stable disease allow provided nonbulky ) Ineligible autologous stem cell transplant Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma , follicular lymphoma progress ≥ 2 prior therapy Patients bulky disease consider debulking chemotherapy prior transplant Patients refractory disease eligible provide disease nonbulky AND estimate tumor double time ≥ 1 month Lymphoplasmacytic lymphoma , mantle cell lymphoma , prolymphocytic leukemia Chemotherapysensitive disease previously treat initial therapy Patients mantle cell lymphoma must progressive disease salvage therapy ( stable disease allow provided nonbulky ) Mycosis fungoides Sezary syndrome Bone marrow failure syndrome , except Fanconi anemia Myeloproliferative syndrome NOTE : *Patients adequate marrow/biopsy specimen obtain determine remission status morphologic assessment must fulfil criterion remission ( &lt; 5 % blast flow cytometry recovery peripheral blood count circulate blast ) Ineligible autologous stem cell transplant due following : Prior autologous stem cell transplant Inadequate autologous stem cell harvest Inability withstand myeloablative preparative regimen Clinically aggressive/highrisk disease No evidence progressive disease image modality biopsy ( persistent PET scan activity allow provide CT scan change indicate progression ) Acute leukemia refractory , persistent , relapse ( define &gt; 5 % blast normocellular bone marrow ) allow provide patient render aplastic either induction chemotherapy radioimmunoconjugated monoclonal antibody therapy Patients stable disease eligible provide large residual nodal mass approximately &lt; 5 cm ( large residual mass must represent 50 % reduction approximately &lt; 7.5 cm patient respond prior therapy ) No active CNS malignancy Umbilical cord blood ( UCB ) donor available UCB graft match 4/6 HLAA , B , DRB1 antigens recipient May include 02 antigen mismatch A , B , DRB1 loci Unit selection base cryopreserved nucleated cell dose HLAA , B , DRB1 use intermediate resolution A , B antigen DRB1 allele type If 2 UCB unit require reach target cell dose , unit must 3/6 HLAA , B , DRB1 antigen match , well 4/6 antigen match recipient No 56/6 HLAA , B , DRB1 match sibling donor available PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 60100 % OR Lansky PS 50100 % Creatinine ≤ 2.0 mg/dL ( adult ) OR creatinine clearance &gt; 40 mL/min ( pediatrics ) Adult patient creatinine &gt; 1.2 mg/dL history renal dysfunction must estimate creatinine clearance &gt; 40 mL/min Not pregnant nursing Negative pregnancy test LVEF ≥ 35 % DLCO &gt; 30 % predict No requirement O_2 No decompensated congestive heart failure No uncontrolled arrhythmia None follow liver disease condition : Fulminant liver failure Cirrhosis evidence portal hypertension bridge fibrosis Alcoholic hepatitis Esophageal varices History bleed esophageal varix , hepatic encephalopathy , correctable hepatic synthetic dysfunction evidence prolongation prothrombin time Ascites relate portal hypertension Bacterial fungal abscess Biliary obstruction Chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL Symptomatic biliary disease Recent mold infection ( e.g. , Aspergillus ) allow provided patient receive ≥ 30 day appropriate treatment AND infection control clear Infectious Disease No evidence HIV infection know HIVpositive serology No uncontrolled viral bacterial infection PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 month since prior myeloablative stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative disease</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
</DOC>